Eric Benevich - Jan 31, 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Commercial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Jan 31, 2025
Transactions value $
-$184,599
Form type
4
Date filed
2/4/2025, 05:35 PM
Previous filing
Dec 12, 2024
Next filing
Feb 12, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +2.29K +5.62% $0.00 43.1K Jan 31, 2025 Direct
transaction NBIX Common Stock Sale -$185K -1.21K -2.8% $152.94 41.9K Jan 31, 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -2.29K -50% $0.00 2.29K Jan 31, 2025 Common Stock 2.29K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Includes an aggregate of 54 shares purchased on August 31, 2024 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F4 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F5 This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,293 shares on January 31, 2023, vested as to 2,294 shares on January 31, 2024, vested as to 2,294 shares on January 31, 2025, and will vest as to 2,294 shares on January 31, 2026, subject to the terms and conditions of the award.